Pegylated liposomal doxorubicin in ovarian cancer

International Journal of Nanomedicine

1, 229-39

#	Article	IF	Citations
1	Chapter 16 Antiangiogenic Photodynamic Therapy with Targeted Liposomes. Methods in Enzymology, 2009, 465, 313-330.	0.4	22
2	Phase I and Pharmacokinetic Study of Pegylated Liposomal CKD-602 in Patients with Advanced Malignancies. Clinical Cancer Research, 2009, 15, 1466-1472.	3.2	61
3	In vivo targeting of B-cell lymphoma with glycan ligands of CD22. Blood, 2010, 115, 4778-4786.	0.6	182
4	Nanotechnology and human health: risks and benefits. Journal of Applied Toxicology, 2010, 30, 730-744.	1.4	128
5	Factors affecting the pharmacokinetics of pegylated liposomal doxorubicin in patients. Cancer Chemotherapy and Pharmacology, 2012, 69, 43-50.	1.1	87
6	Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin. Human Cell, 2013, 26, 8-18.	1.2	61
7	Can nanomedicines kill cancer stem cells?. Advanced Drug Delivery Reviews, 2013, 65, 1763-1783.	6.6	114
8	Metformin, at Concentrations Corresponding to the Treatment of Diabetes, Potentiates the Cytotoxic Effects of Carboplatin in Cultures of Ovarian Cancer Cells. Reproductive Sciences, 2013, 20, 1433-1446.	1.1	52
9	Quercetin-induced cardioprotection against doxorubicin cytotoxicity. Journal of Biomedical Science, 2013, 20, 95.	2.6	54
10	Review Trabectedin as aÂsingle agent and in combination with pegylated liposomal doxorubicin â€“ activity against ovarian cancer cells. Wspolczesna Onkologia, 2014, 3, 149-152.	0.7	2
11	Nuclear Proteomics with XRCC3 Knockdown to Reveal the Development of Doxorubicin-Resistant Uterine Cancer. Toxicological Sciences, 2014, 139, 396-406.	1.4	7
12	Nanolipolee-007, a Novel Nanoparticle-Based Drug Containing Leelamine for the Treatment of Melanoma. Molecular Cancer Therapeutics, 2014, 13, 2328-2340.	1.9	23
13	Identification of up- and down-regulated proteins in doxorubicin-resistant uterine cancer cells: Reticulocalbin-1 plays a key role in the development of doxorubicin-associated resistance. Pharmacological Research, 2014, 90, 1-17.	3.1	10
14	Nanomedicine concepts in the general medical curriculum: initiating a discussion. International Journal of Nanomedicine, 2015, 10, 7319.	3.3	19
15	Mitochondrial proteomics with si<scp>RNA</scp> knockdown to reveal <scp>ACAT</scp>1 and <scp>MDH</scp>2 in the development of doxorubicinâ€resistant uterine cancer. Journal of Cellular and Molecular Medicine, 2015, 19, 744-759.	1.6	36
16	Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis. Scientific Reports, 2015, 5, 9301.	1.6	48
17	Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literature. Oncology Letters, 2016, 12, 5332-5334.	0.8	22
18	Antibodyâ€“drug conjugates and other nanomedicines: the frontier of gynaecological cancer treatment. Interface Focus, 2016, 6, 20160054.	1.5	13

#	Article	IF	Citations
19	Liposome Delivery Systems for Inhalation: A Critical Review Highlighting Formulation Issues and Anticancer Applications. Medical Principles and Practice, 2016, 25, 60-72.	1.1	132
20	The licorice dietary component isoliquiritigenin chemosensitizes human uterine sarcoma cells to doxorubicin and inhibits cell growth by inducing apoptosis and autophagy via inhibition of m-TOR signaling. Journal of Functional Foods, 2017, 33, 332-344.	1.6	22
21	A brief review of the management of platinum-resistantâ€"platinum-refractory ovarian cancer. Medical Oncology, 2017, 34, 103.	1.2	125
22	Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy. Nature Communications, 2017, 8, 15507.	5.8	56
23	Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer. Medicine (United States), 2017, 96, e5797.	0.4	3
24	A chemo/photo- co-therapeutic system for enhanced multidrug resistant cancer treatment using multifunctional mesoporous carbon nanoparticles coated with poly (curcumin-dithiodipropionic) Tj ETQq1 1 0.784314 rgBT /Overlock 1	3.4	18
25	Enzyme-catalyzed functionalization of poly(L-lactic acid) for drug delivery applications. Process Biochemistry, 2017, 59, 77-83.	1.8	42
26	Liposome-Mediated Immunosuppression Plays an Instrumental Role in the Development of â€œHumanized Mouseâ€• to Study Plasmodium falciparum. , 2017, , .		0
27	A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer. Oncotarget, 2017, 8, 19125-19136.	0.8	6
28	Cell-Derived Vesicles for in Vitro and in Vivo Targeted Therapeutic Delivery. ACS Omega, 2019, 4, 12657-12664.	1.6	16
29	Nanocarrier-based systems for targeted and site specific therapeutic delivery. Advanced Drug Delivery Reviews, 2019, 144, 57-77.	6.6	171
30	Peptidylarginine deiminase 4 overexpression resensitizes MCF-7/ADR breast cancer cells to adriamycin via GSK3β/p53 activation. Cancer Management and Research, 2019, Volume 11, 625-636.	0.9	11
31	Optimization of Lecithin-Chitosan nanoparticles for simultaneous encapsulation of doxorubicin and piperine. Journal of Drug Delivery Science and Technology, 2019, 52, 204-214.	1.4	34
32	Chemotherapy and cognition: comprehensive review on doxorubicin-induced chemobrain. Cancer Chemotherapy and Pharmacology, 2019, 84, 1-14.	1.1	65
33	Nanotechnology and Immunotherapy in Ovarian Cancer: Tracing New Landscapes. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 636-646.	1.3	24
34	Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 2210-2219.	3.3	173
35	Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer. Abdominal Radiology, 2020, 45, 828-841.	1.0	2
36	Organ Biodistribution of Radiolabelled Î³Î´ T Cells Following Liposomal Alendronate Administration in Different Mouse Tumour Models. Nanotheranostics, 2020, 4, 71-82.	2.7	12

#	Article	IF	Citations
37	Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer. JCO Global Oncology, 2020, 6, 542-547.	0.8	11
38	Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy. Seminars in Cancer Biology, 2021, 69, 337-348.	4.3	62
39	Anti-Proliferative Effect of Doxorubicin-Loaded AS1411 Aptamer on Colorectal Cancer Cell. Asian Pacific Journal of Cancer Prevention, 2021, 22, 2209-219.	0.5	13
40	A mini-review of Nanocarriers in drug delivery systems. British Journal of Pharmacy, 2022, 7, .	0.1	2
41	Reactive Oxygen Species-Mediated Inflammation and Apoptosis in Hand-Foot Syndrome Induced by PEGylated Liposomal Doxorubicin. International Journal of Nanomedicine, 2021, Volume 16, 471-480.	3.3	14
42	Preclinical activity of melflufen (J1) in ovarian cancer. Oncotarget, 2016, 7, 59322-59335.	0.8	13
43	Evolution of Chemosensitivity and Resistance Assays as Predictors of Clinical Outcomes in Epithelial Ovarian Cancer Patients. Current Pharmaceutical Design, 2016, 22, 4717-4728.	0.9	19
44	Real world effectiveness and safety of pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian, fallopian, or primary peritoneal cancer: a Korean multicenter retrospective cohort study. Journal of Gynecologic Oncology, 2020, 31, e15.	1.0	5
45	Specific Targeting of PEGylated Liposomal Doxorubicin (DoxilÂ®) to Tumour Cells Using a Novel TIMP3 Peptide. Molecules, 2021, 26, 100.	1.7	8
46	Mining to find the lipid interaction networks involved in Ovarian Cancers. Summit on Translational Bioinformatics, 2009, 2009, 61-5.	0.7	1
47	Nanotechnology and Pediatric Cancer: Prevention, Diagnosis and Treatment. Iranian Journal of Pediatric Hematology and Oncology, 2015, 5, 233-48.	0.4	5
49	An Overview of Nanotechnologies for Drug Delivery to the Brain. Pharmaceutics, 2022, 14, 224.	2.0	34
50	Dimeric Artesunate Glycerophosphocholine Conjugate Nano-Assemblies as Slow-Release Antimalarials to Overcome Kelch 13 Mutant Artemisinin Resistance. Antimicrobial Agents and Chemotherapy, 2022, 66, e0206521.	1.4	11
51	Translational development of a tumor junction opening technology. Scientific Reports, 2022, 12, 7753.	1.6	3